
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Pacira BioSciences, Inc. (PCRX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: PCRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $30.6
1 Year Target Price $30.6
1 | Strong Buy |
1 | Buy |
3 | Hold |
1 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.05% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.11B USD | Price to earnings Ratio - | 1Y Target Price 30.6 |
Price to earnings Ratio - | 1Y Target Price 30.6 | ||
Volume (30-day avg) 6 | Beta 0.48 | 52 Weeks Range 12.61 - 27.64 | Updated Date 08/15/2025 |
52 Weeks Range 12.61 - 27.64 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.75 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate 0.7171 | Actual 0.74 |
Profitability
Profit Margin -18.06% | Operating Margin (TTM) 5.04% |
Management Effectiveness
Return on Assets (TTM) 2.69% | Return on Equity (TTM) -15.57% |
Valuation
Trailing PE - | Forward PE 8.83 | Enterprise Value 1308407697 | Price to Sales(TTM) 1.58 |
Enterprise Value 1308407697 | Price to Sales(TTM) 1.58 | ||
Enterprise Value to Revenue 1.85 | Enterprise Value to EBITDA 48 | Shares Outstanding 44932700 | Shares Floating 42194970 |
Shares Outstanding 44932700 | Shares Floating 42194970 | ||
Percent Insiders 1.82 | Percent Institutions 116.28 |
Upturn AI SWOT
Pacira BioSciences, Inc.

Company Overview
History and Background
Pacira BioSciences, Inc. was founded in 2006. It focuses on developing, commercializing and manufacturing non-opioid pain management and regenerative health solutions.
Core Business Areas
- Pain Management: The core business revolves around non-opioid pain management, primarily through EXPAREL, their flagship product. This segment also includes Iovera and ZILRETTA products used in human therapeutic applications.
Leadership and Structure
Pacira is led by Frank D. Lee as Chief Executive Officer. The company has a typical corporate structure with departments for R&D, manufacturing, sales, marketing, finance, and administration. The board of directors provides oversight.
Top Products and Market Share
Key Offerings
- EXPAREL (bupivacaine liposome injectable suspension): EXPAREL is a long-acting, local analgesic indicated for single-dose infiltration to produce postsurgical analgesia and as an interscalene brachial plexus nerve block to produce postsurgical analgesia. Main competitors include generic local anesthetics and opioid-based pain management solutions. Estimated that EXPAREL has about 20-30% market share in the long-acting local anesthetic segment. Revenue from EXPAREL contributes the majority of Pacira's total revenue.
- Iovera System: Iovera is a handheld cryoanalgesia device that delivers focused cold therapy to targeted nerves, providing immediate pain relief without opioids. Competitors include nerve blocks and other non-opioid and opioid pain treatments. The exact market share is not publicly available, but it's smaller than EXPAREL.
- ZILRETTA (triamcinolone acetonide extended-release injectable suspension): ZILRETTA, an injectable medicine, is used for adults to manage moderate to severe osteoarthritis (OA) knee pain. Competitors include other injectable and non-injectable corticosteroids and hyaluronic acid viscosupplements.
Market Dynamics
Industry Overview
The pain management market is growing due to the aging population, increasing surgical procedures, and rising awareness of non-opioid pain management options. There's a strong push for alternatives to opioids due to the opioid crisis.
Positioning
Pacira is positioned as a leader in the non-opioid pain management space, primarily through its innovative EXPAREL product. They are well positioned to capitalize on the growing demand for opioid alternatives.
Total Addressable Market (TAM)
The global pain management market is estimated to be over $80 billion. Pacira's focus on non-opioid solutions gives them access to a significant portion of this TAM, particularly the surgical and osteoarthritis pain segments.
Upturn SWOT Analysis
Strengths
- Proprietary drug delivery technology (EXPAREL)
- Strong market position in non-opioid pain management
- Growing demand for opioid alternatives
- Established sales and marketing infrastructure
- Expanding product portfolio
Weaknesses
- Reliance on EXPAREL for revenue
- Patent expiry risks for EXPAREL
- Competition from generic local anesthetics
- Regulatory and reimbursement challenges
Opportunities
- Expanding indications for EXPAREL
- Acquiring or licensing new products
- Penetrating new geographic markets
- Partnering with hospitals and surgery centers
Threats
- Generic competition for EXPAREL
- Pricing pressures from payers
- Changes in regulatory landscape
- Development of competing non-opioid pain management technologies
- Economic downturn
Competitors and Market Share
Key Competitors
- BAX
- ITCI
- HGEN
Competitive Landscape
Pacira holds an advantage in the non-opioid postsurgical pain market with EXPAREL's sustained release formulation. Baxter offers a broader portfolio of products. ITCI and HGEN are key innovators in the space, but generally, EXPAREL has a market leadership position, though competition is growing.
Major Acquisitions
Flexion Therapeutics
- Year: 2021
- Acquisition Price (USD millions): 441
- Strategic Rationale: Expanded Pacira's portfolio with ZILRETTA, a non-opioid treatment for osteoarthritis knee pain.
Growth Trajectory and Initiatives
Historical Growth: Pacira has experienced strong growth over the past decade, driven by the commercial success of EXPAREL and strategic acquisitions.
Future Projections: Analysts project continued growth for Pacira, driven by increasing demand for non-opioid pain management solutions and expansion of EXPAREL's indications. Revenue is expected to continue to increase, with EPS to follow.
Recent Initiatives: Recent initiatives include expanding the indications of EXPAREL, exploring new partnerships, and focusing on acquisitions.
Summary
Pacira BioSciences is a strong company in the non-opioid pain management space, particularly with EXPAREL. They are well-positioned to benefit from the shift away from opioids. Key areas to watch are generic competition for EXPAREL and the successful integration of acquired products, as well as economic impacts on surgery rates.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Research Reports
- SEC Filings
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and after consulting with a qualified financial advisor. Market share data are estimates. Financial data provided are approximates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pacira BioSciences, Inc.
Exchange NASDAQ | Headquaters Tampa, FL, United States | ||
IPO Launch date 2011-02-03 | CEO & Director Mr. Frank D. Lee | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 788 | Website https://www.pacira.com |
Full time employees 788 | Website https://www.pacira.com |
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. The company has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.